HDCN Abstract:  ASN Annual Meeting 2020 -- Digital Meeting  

Gama R, Clery A, Palmer KR, et al.

Estimated Glomerular Filtration Rate Equations: Do We Need to Use the Ethnicity Correction Factor in People of African Ancestry Outside of the United States?

ASN Annual Meeting 2020 -- Digital Meeting
J Am Soc Nephrol (Oct) 31:19A 2020


Recent African studies suggest ethnicity factors in estimated glomerular filtration rate (eGFR) equations is not required.


To assess accuracy of eGFR equations, with and without ethnicity factors compared with gold standard 51Cr-ethylenediaminetetraacetic acid (51Cr-EDTA) clearance assays. Patients with albumin <30g/dl, hepatology referrals, <18 years old, non-white or black, mixed ethnicities were excluded. Accuracy of CKD-EPI and MDRD equations compared to 51Cr-EDTA GFR were assessed with and without correction factor.


2,776 51Cr-EDTA studies were identified (Mean age-54yrs; 43% female; 12% Black ethnicity). In Black patients, CKD-EPI and MDRD eGFR equations significantly overestimated GFR compared to White (p<0.001) but without ethnicity correction factor estimates were considerably improved (p<0.001)(Table 1). Accuracy was superior for GFR≥60ml/min/1.73m2 compared to <60ml/min/1.73m2 using CKD-EPI equation for both White and Black patients (p<0.001).


Overestimation of measured GFR with eGFR equations using ethnicity correction factors identified in this study may lead to reduced rates of CKD diagnosis and under -recognition of CKD severity in people of Black ethnicity in the UK. These findings require prospective validation in other countries.

   GFR Mean (SD)BiasPrecisionLimits of agreement30% Accuracy (%)
BlackCorrected 51Cr- EDTA
GFR <60
Corrected 51EDTA41.0 (13.8)    
CKD-EPI adjusted59.4 (27.3)18.419.8-21.2 to 5839.3
CKD-EPI unadjusted51.2 (23.6)10.216.7-23.2 to 43.655.4
MDRD adjusted57.2 (24.8)16.217.5-18.8 to 51.248.2
MDRD unadjusted47.2 (20.5)6.214.1-22.0 to 34.464.3
Corrected 51Cr-EDTA ≥GFR 60
Corrected 51EDTA87.2 (16.0)    
CKD-EPI adjusted107.9 (22.3)20.721.9-23.1 to 64.559.4
CKD-EPI unadjusted93.1 (19.3)5.919.7-33.5 to 45.381.1
MDRD adjusted107.3 (30.2)20.128.1-36.1 to 76.359.4
MDRD unadjusted88.5 (24.9)1.323.7-46.1 to 48.777.5
WhiteCorrected 51Cr- EDTA
GFR <60
Corrected 51EDTA46.6 (11.2)    
CKD- EPI64.2 (21.2)17.616.1-14.6 to 49.844.1
MDRD61.4 (21.6)14.817.1-19.4 to 49.051.4
Corrected 51Cr- EDTA ≥GFR 60
Corrected 51EDTA83.2 (15.4)    
CKD- EPI96.7 (16.0)13.514.9-16.3 to 43.374.4
MDRD97.7 (25.2)14.522.8-31.1 to 60.170.0

Adjusted = including ethnicity correction factor; Unadjusted = excluding ethnicity correction factor

c Copyright 2020 -2021 American Society of Nephrology. Reproduced with permission.
All ASN abstracts from the 2020 Annual Meeting are available at this link and also are archived in .pdf form at ASN-Online.org

Disclaimer: Abstracts often have errors, both typographical and otherwise. This posting is an electronic translation of submitted abstracts which has not been verified against the original submitted abstract nor with the authors for accuracy. As a result, there may be errors, especially with regard to drug doses, but not limited to these. Abstracts undergo only limited review, and data often are changed as a result of the peer review process, so their reliability is less than manuscripts published in peer-reviewed journals. In using these summaries, you are agreeing that you are aware of these limitations.

The materials are provided on an as-is basis without any warranty of any kind, either express or implied. In addition to errors, the information presented may be incomplete or outdated. The information contained is not intended nor recommended as a substitute for professional medical advice. You are advised to check the appropriate medical literature and the product information currently provided by the manufacturer of each device to be used or drug to be administered to verify the dosage, the method and duration of administration, or contraindications. It is the responsibility of the treating physician or other health care professional, relying on independent experience and knowledge of the patient, to determine drug, disease, and the best treatment for the patient.

To the fullest extent permitted by law, HDCN, ASN and their affiliates and suppliers disclaim all warranties, express or implied, including, but not limited to, any warranty of merchantability, non- infringement or fitness for a particular purpose.

In no event shall HDCN, ASN, or their affiliates or suppliers be liable for any damages whatsoever (including, but not limited to, direct, indirect, incidental, consequential, punitive or exemplary damages, or any damages for loss of profits, use, data, goodwill or other intangibles) arising from or in any way relating to these terms, the materials, or any information, goods or services obtained from or referred to in the materials, whether based on warranty, contract, tort (including, but not limited to, negligence), or any other legal theory, and whether or not any or all of the limited entities is advised of the possibility of such damages.